



FAIRCHEM ORGANICS LIMITED

Works & Office : 253/P & 312, Village Chekhala, Sanand - Kadi Highway,

Taluka : SANAND, Dist.: Ahmedabad 382 115, INDIA.

Phone (Board Nos.) : (02717) 687900, 687901, +91 90163 24095

E-mail : cs@fairchem.in

CIN : U24200MH2019PLC323176

Website : www.fairchem.in

Date: October 30, 2021

To,

National Stock Exchange of India Ltd.

Exchange Plaza,

Plot no. C/1, G Block, Bandra-kurla Complex

Bandra (E)

Mumbai – 400 051.

To,

**Department of Corporate Services,
BSE Limited.**

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001.

BSE Code: 543252 and NSE Symbol: 'FAIRCHEMOR'

Dear Sirs,

Sub.: Publishing Financial Statements pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Please find With reference to above, we wish to inform you that we have placed on BSE Listing Centre (for BSE) and NEAPS (for NSE), the financial results of the Company for the quarter & half year ended September 30, 2021 published on Saturday, October 30, 2021 the following newspapers in their Mumbai edition:

1. The Economic Times (English)
2. Maharashtra Times (Marathi)

The above is in accordance pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015.

Please find the above in order and take the same on your record.

Thanking you,

Yours faithfully,

For Fairchem Organics Limited,

Rajen Jhaveri

Chief Financial Officer & Company Secretary

Encl: as above

OPENINGS AT A NEW HIGH Economic recovery and vaccination progress boost optimism; tech skills lead demand on greater digitisation Fireworks Start in Job Market Ahead of Diwali

Sreeradha.Basu@timesgroup.com

Bengaluru: Ahead of Diwali, the Indian job market is seeing the record bounceback from Covid-19 lows on the back of increased business optimism, economic recovery and mass vaccination rollout. Job openings are at a new high and the competition for talent — especially those in technology — is at a level not seen in many years, more than half-a-dozen recruitment firms and job sites told ET. Mandates are up by a minimum of 15-25% compared to pre-Covid levels and at the top end, they have more than doubled, according to firms including Randstad India, ABC Consultants, Antal India, CIE HR, TeamLease Services and data from job site Indeed.

"This frenzy is something we haven't seen in the last two decades," said Sanjay Shetty, director - professional search & selection and strategic accounts at Randstad India.

Leading the demand is the technology and the tech-related sector as the industry has accelerated the move towards digitisation even in traditional industries.

Financial services and fintech, retail, logistics and e-commerce, healthcare and pharma, consumer, and manufacturing are all seeing a strong surge in numbers.

Job openings on Indeed on October 22 were a record 18% above the pre-pandemic baseline (February 2020). "Thanks to Covid-19 retreating and a strong vaccination drive, job growth continues to accelerate," said Sashi Kumar, head of sales at Indeed India. "More workers are finding jobs or starting to pick up their job search."

Shri Agrawal, managing director of ABC Consultants, said multiple factors are driving the job market boom. The 'Great Resignation' and consequent high attrition is causing a surge in replacement hiring and there is pent-up demand from companies who had put hiring plans on hold during the pandemic.

"There are new investments, companies have had healthy profits, there's an appetite to hire," Agarwal said.

at recruitment firm Antal India, said mid-level hiring is seeing the highest spike currently, followed by leadership hiring. "Post the Great Resignation of 2020, we witnessed a surge in hiring; right now, we are seeing a similar or higher surge," he said.

Mid-level hiring is also seeing the sharpest surge at TeamLease Services, where over a year-on-year growth of 89% in August. It also surpassed the pre-pandemic levels of August 2019 by 24%.


"The surge in hiring activities in the October-December quarter compared to the year-ago period is being led by the engineering and manufacturing as well as the technology sectors," said TeamLease cofounder Rituparna Chakrabarty.

CIE HR Services has seen a 50% jump compared to the same time last year and a nearly 15-20% rise vis-a-vis the pre-Covid times.

"The rise is largely powered by the investments flowing into the startup ecosystem and technology-led companies," the company CEO Aditya Narayan Mishra said. "And secondly, it is due to the accelerated investments in digitisation by companies across the globe."

Axis Bank has added people across various verticals including technology, new skills, corporates among others. "Optimism is definitely there... We are hiring in a big way" the private bank's HR head Rajkamal Vempati said.

Edtech unicorn EduTus plans to nearly double the headcount for its India business over the next 12 months across various functions, but particularly instructional design, marketing and sales. "We are very bullish. It's getting tougher to hire good talent in this market but there are a lot of opportunities," its CEO Ashwin Damara said.



id. "During the pandemic, companies have restructured, now the floodgates have opened. September and October have been right up there with our best months ever." He said he is happy to turn down client requests because of the hiring surge.

Joseph Devasia, managing director

No Shortcuts Used to Develop Covaxin

RENU SWARUP
SECRETARY, DEPT OF BIOTECHNOLOGY

Renu Swarup, secretary, department of biotechnology, has been at the helm of the government's efforts to boost vaccine development in the country. In an interview with Teena Thacker ahead of her retirement on October 31, she discussed Covid-19 vaccine Covaxin, which is struggling to get approval from the WHO. mRNA vaccines and how the pandemic has bolstered India's preparedness for various medical eventualities. Edited excerpts:

What would you say about this journey of one-and-a-half years?
From January of 2020 to where we are today, it has been a remarkable journey, in the sense that we were suddenly faced with this new challenge and the effective response has been so wonderful. The best is that this time, when we completed 100 crore doses, the prime minister said it's a triumph of science, and that truly says everything. Of course, the major role has been played by the citizens — we had to come forward, whether it was for vaccination, adopting Covid-appropriate behaviour, etc. This has given us the confidence

that India now has the ecosystem which has responded to this pandemic, and for any future emergency, we are geared up to respond.

What were the major challenges for research work and vaccine development in the times of Covid?
The biggest challenge was when the pandemic came in, we had all the groups working on it, but with the lockdown, supply chain disruptions and travel restrictions, we were not used to virtual connections. We had to identify our gaps, needs, creating an immediate framework and a road map and then working in it to be able to come forward. Scientists

were used to a different way. Things changed. For example, the movement of samples... You are using resources and everything is not there where you are. You are doing studies at one place, but need to go to another place for animal studies. So I think that was the bigger challenge.

Did India have enough funds to deal with the situation?
We were given mission Covid Suraksha of ₹900 crore. We could bring together academic stakeholders, industry and startups. There was another research consortium we put in. The CSIR, DST, NII Aayog, ICMR — everyone put in the research grants. It's difficult to put a number to it. But it was a whole government approach, together we tried to pool in resources from wherever they were. I think this has been the best that everyone has worked across departments without any boundaries. I can say wherever there was any requirement we have not suffered due to lack of funds. The ecosystem we built in the last 15 years has been the most robust.

DST closely monitored development of vaccines, especially Covaxin. Given the delay in getting WHO approval, do you think corners were cut in

developing Covaxin?

Not at all. There's no question of compromise. We have accelerated the response. There's no shortcut. What we have been able to do is help many actions happen in a parallel manner, rather than waiting for it to be done sequentially. Importantly, it was sharing of knowledge and data that made it so much faster. We have shared a lot of data, knowledge and best practices, nationally and globally, and this is the learning that will take us beyond Covid for many others.

What potential does mRNA hold?
It has a huge potential. It's a wonderful platform. What is important is that being the nuclei acid, it has the ability for being pan-coronavirus, as we say, to tackle the variants very easily.

FOR FULL REPORT, GO TO www.economicstimes.com

DRL Plans Sputnik Light Trials for Children

Viswanath.Pilla@timesgroup.com

Mumbai: Dr Reddy's Laboratories (DRL) on Friday said it plans to launch separate clinical trials of the single-shot Covid-19 vaccine, Sputnik Light, on children and as a booster for other vaccines.

The company plans to begin both trials with the Russia-developed vaccine in November.

The drugmaker is finalising the protocol to begin the trials on children and adolescents which will have two cohorts — one for

ective of API & services at DRL, told media.

Sputnik Light is also being tested on children in Russia.

For its test as a booster dose, the company said it has finalised the protocol. The company intends to use the booster with a gap of six months.

Q2 NET JUMPS 30%
The company Friday reported a 30 per cent jump in its consolidated profit to ₹92 crore for the quarter ended September 30, 2021, on account of robust sales in all markets.



Oyo Counters Zostel's Letter to Sebi Against Proposed Public Issue

No restriction on changing shareholding pattern, no HC stay on IPO, aggregator writes to Zostel and Sebi

Anumeha.Chaturvedi@timesgroup.com

New Delhi: SoftBank backed hospitality firm Oyo has hit back at Zostel with a letter refuting its claims and updated the Securities and Exchange Board of India on its disputes with the smaller rival.

Zostel had sent a letter to the markets regulator which called for rejecting Oyo's draft prospectus and suspending its proposed initial public offering. It claimed that Oyo's IPO was "non-maintainable" as its capital structure was not "final".

In its letter to Zostel, which was also marked to Sebi and accessed by ET, Oyo has written that the restriction has been imposed on Oyo from changing its shareholding pattern, either by a Supreme Court-appointed arbitrator's award or by the Delhi High Court. "Further, no stay has been granted by the Delhi High Court on the proposed offer despite a prayer to this effect by Zostel," Oyo wrote.

According to Zostel Hospitality, which runs Zostel hotels and Zo Rooms, Oyo had in 2015 agreed to acquire Zo Rooms but breached the term sheet signed on November 26, 2015, by not executing the deal. Oyo had promised shareholders of Zo Rooms a 7% stake, it has claimed.

A court-appointed arbitrator had ruled that Oyo was bound by the terms agreed upon which required the company to cede up to 7% of its equity Oyo has challenged the arbitrator's award in the Delhi High Court and has rejected Zostel's claim that its shareholders ought to receive a 7% stake.

Oyo wrote in its letter that in September 2016, both parties mutually agreed to terminate the non-binding term sheet due to various issues, in-



cluding non-completion of the due-diligence process and transaction structuring raised by Zostel.

Oyo also wrote that certain assets, which were to be transferred to it as part of the proposed transaction, were never transferred by Zostel and in its understanding, continued to be retained. "During the course of the arbitration or otherwise, Zostel failed to provide any evidence to substantiate its claim that its assets/business were transferred to the company," the financial statements of Zostel show that as of 31.03.2018, Zostel had a huge set of assets which shows that "Zostel had not transferred anything to the company," Oyo wrote.

Oyo also mentioned in its letter that do not have any pending rights, co-ownership of CRS, Zo Rooms and Ozonet App, Zo Rooms customer email app notification, tool access, Twitter handle, Facebook and Instagram pages, TripAdvisor, Google listing access and hotel description content for all hotels were among the things not transferred to the company.

The company also stated that in furtherance of its due diligence for the proposed transaction with Zostel, the company had shared data with Oyo which were "incomplete" and replete with "inaccuracies".

Global fatality count crosses 5m

CASES ON FRIDAY: 14,150*

ACTIVE CASES: 155,734 (+559*)

Recovered: 53.65 M (+13,042)

Deaths: 457,772 (+549*)

TOTAL CASES: 34.26 M

VACCINE DOSES ADMINISTERED IN INDIA: 1053.76M (+5.55M)

1st dose: 730.46 m **2nd dose: 132.09 m**

DOSES ADMINISTERED

Top 10 States	FRI	Total
West Bengal	981,899	76.40 m
UP	849,787	130.10 m
AP	454,550	52.88 m
Maharashtra	423,511	176.55 m
Telangana	366,436	31.81 m
Gujarat	338,702	70.26 m
Karnataka	286,202	65.08 m
Odisha	246,859	17.09 m
Rajasthan	211,599	62.39 m
MP	205,032	70.07 m

VACCINE DOSES ADMINISTERED GLOBALLY (204 countries/areas): 6989.50M

Top 5*	DOSES	Enough for % of population
Mainland China	254,25 m	80.5
US	417,80 m	65.2
Brazil	272,67 m	61.9
Indonesia	168.78 m	35.4
Japan	180.87 m	74.4

Samples Tested so Far*

605.89 MILLION **1.28 M** in last 24 hours

POSITIVE TESTS* 5.66%

Daily Infections

5 worst-hit states	CASES ON FRI	DEATHS
Kerala	7,722	86*
Maharashtra	1,338	36
Tamil Nadu	1,039	11
West Bengal	982	8
Mizoram	592	2

SHARE IN DAILY CASES: 82.49%

5 Main Metros	CASES ON FRI	ACTIVE CASES
Mumbai	330	4955
Kolkata	273	2185
B'uru Urban	179	6543
Chennai	116	1477
Delhi	37	334

GLOBAL COUNT

Total Cases: 246.56 M **Recovered: 223.36 M**

Deaths: 5,000,833

FAIRCHEM ORGANICS LIMITED

Regd. Office: Plot No. A-71, TTC, Thane-Belapur Road, Near Kopar Khairane, NAVI MUMBAI-400 709
 Works & Office : 253/P & 312, Village Chekhala, Sanand - Kadi Highway, Taluka Sanand, Dist. Ahmedabad - 382 115, Gujarat. Ph.: (02717) 687 900, (02717) 687 901
 Email Id: cs@fairchem.in, Website: www.fairchem.in
 CIN: U24200MH2019PLC323176

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2021

Sr. No.	Particulars	Quarter ended			Six Months ended			Year ended
		30-Sep-2021	30-Jun-2021	30-Sep-2020	30-Sep-2021	30-Sep-2020	31-Mar-2021	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Total Income from operations	16,802.62	13,953.33	9,499.98	30,736.10	13,009.33	39,685.16	
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	2,801.86	2,993.30	1,221.75	5,795.16	1,354.27	5,556.08	
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	2,801.86	2,993.30	1,221.75	5,795.16	1,354.27	5,556.08	
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	2,089.74	2,231.20	905.75	4,320.94	1,025.18	4,248.47	
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	2,088.40	2,216.05	911.30	4,304.45	1,020.73	4,201.38	
6	Equity Share Capital (Face value of Rs. 10/- each)	1,302.09	1,302.09	1,302.09	1,302.09	1,302.09	1,302.09	
7	Other Equity (as per balance sheet of the previous accounting year)						15,571.36	
8	Earnings Per Share (Face value of Rs. 10/- each) - IN Rupees							
	Basic	16.05	17.14	6.96	33.18	7.87	32.63	
	diluted	16.05	17.14	6.96	33.18	7.87	32.63	

Notes:
 1 The above is an extract of the detailed format of Unaudited Financial Results for the quarter and six months ended September 30, 2021 filed with the Stock Exchanges under Regulation 33 of SEBI (LODR) Regulations, 2015. The full format of the Financial Results are available on the websites of the Stock Exchanges (www.bseindia.com, www.nseindia.com) and the Company (www.fairchem.in)

For and on behalf of the Board of Directors,
 For Fairchem Organics Limited,

Sd/-
 Nahoosh Jariwala
 Managing Director
 DIN 00012412

Place : Chekhala, Taluka Sanand, Dist. AHMEDABAD
 Date : October 28, 2021

GSK Pharma Sept Quarter Net Soars Over Twofold

New Delhi: GlaxoSmithKline (GSK) Pharmaceuticals on Friday posted an over two-fold increase in its consolidated net profit to ₹244 crore for the third quarter ended September 30, 2021.

"The company had reported a net profit of ₹77 crore in the same period of the previous fiscal. Consolidated revenue from operations rose to ₹1,08,857 crore in the period under review as against ₹979.32 crore in the year-ago period, GSK Pharmaceuticals said in a filing. The company follows a January-December financial period.

"Our established brands grew in their respective therapeutic portfolios, Augmentin and Calpol regained their place amongst the top five brands," said MD Sridhar Venkatesh. —PTI

SLUM REHABILITATION AUTHORITY

No:Tha-1 (SC)/Acq/kadeshwari CHS/21-41777. Date : 29 OCT 2021

PUBLIC NOTICE

It is hereby informed that the office has received a proposal to acquire land for implementation of Slum Rehabilitation Scheme under Section 14(1) of the Maharashtra Slum Areas (Improvement, Clearance & Redevelopment) Act, 1971 as mentioned in the table below. The proposal is for Shree Kadeshwari Co. Op. Housing Society (Prop.)

Sr. No.	Village & Taluka	CTS No.	As per Property Card Area (Sq.Mtr.)	Acquired Area (Sq.Mtr.)	Name of Land Owner/ Imia Malak
1	Vandre Tal-Andheri	B/960	9371.4	1596.40	Shri. Bishop Pereira Bisilica of Mount Mary Vandre
Total				1596.40 Sq.Mtr.	

Land owner or anybody who claims to have any right, title or interest (if any) is having any objection in respect of the proposed acquisition of the aforesaid property as acquired may submit written objection to slum rehabilitation authority within a period of 30 days from the date of publication of this notice.

(SATISH LOKHANDE)
 CHIEF EXECUTIVE OFFICER
 SLUM REHABILITATION AUTHORITY

Administrative Building, Prof. Anant Kanekar Marg, Bandra(East), Mumbai-400051.
 Tel No.: 022-26565800; Fax: 91-22-26580457; Email: info@slra.gov.in

आघाडीतील नेत्यांच्या बदनामीचे कारस्थान

राष्ट्रवादीचे प्रदेशाध्यक्ष जयंत पाटील यांचा आरोप



म. टा. प्रतिनिधी, मुंबई

भाजपचे प्रदेशाध्यक्ष चंद्रकांत पाटील हे हल्ली होपेवरील बोलतात असे कानवार आले आहे. त्यामुळे त्यांचे बोलणे जास्त मननरथेक भेऊ, अशा शब्दांत राष्ट्रवादी काँग्रेसचे प्रदेशाध्यक्ष तथा जलसंधारणमंत्री जयंत पाटील यांनी शुक्रवारी त्यांच्यावर टीका केली. तसेच भाजपचे प्रदेशाध्यक्ष जयंत पाटील यांच्याकडून चौकशीचा सरोसिरा लागू नसून राज्यातील माहितीकृत आघाडीच्या नेत्यांनी बदनामी करणारे कारस्थान सुरू आहे, असा आरोपही त्यांनी पाठविलेला केला.

'भाजपमध्ये गेल्यावर सगळ्याला अभय'

'भारतात १२० कोटी लोकसंख्या असतानाही केंद्रीय रांगेला केवळ महाराष्ट्रातील आणि त्यांच्याविषयी बोलणारे, त्यातही केवळ राष्ट्रवादी, शिवसेना आणि काँग्रेस या पक्षांतून नेते दिसत आहेत. बाकी पक्षातील नेते हे धुतूया तांदळासारखे आहेत काय? भाजपमधील खासदारच सुमेलतात की, आता आम्हाला राजीव शंत होणे लागते. महणजेच भाजपमध्ये त्यांनी गेल्या की सगळ्याला अभय आहे. परंतु विरोधात आवाज उठवला की त्यांची १०-२० वर्षांपूर्वीची कागदपत्रे, चौकशीचा सरोसिरा सुरू करावाच, धाडी टाकायच्या, त्यांची बदनामी करण्याची असे काय केंद्रीय संघणा करत आहेत. हे दुर्दैवी आहे, असे पाटील म्हणाले.

जयंत पाटील यांनी कोकण दौऱ्यात गाणवतीपुळे येथे वरील आरोप केला. चंद्रकांत पाटील हे राज्य सरकारवर टीका करत असले तरी त्यांना इतके महत्त्व देणे गरजेचे नाही, असेही ते म्हणाले. भाजपने एका अधिकाऱ्याबाबत इतके गोपनीयते घेण्याची गरज नाही. राष्ट्रवादीचे नेते जयंत पाटील यांनी याबाबत उग्रद्वेष व्यक्तित्व असून, त्यांचा समीर बान्खेडे उतर देतील. मात्र पाटील यांनी नमूद केले.

जुन्या पेन्शन योजनेसाठी आंदोलन

म. टा. प्रतिनिधी, मुंबई

राज्य सरकारने कर्मचाऱ्यांना जुनी पेन्शन योजना पुन्हा लागू करण्यात यावी, या मागणीसाठी मुंबईसह राज्यभरात सरकारी कर्मचाऱ्यांनी

दरम्यान, नवीन अंशदायी पेन्शन योजना कर्मचाऱ्यांविहाची नाही. ती सुरू झाल्यापासून गेल्या १६ वर्षांतून मात्र पावलेल्या एक हजार ६३२ कर्मचाऱ्यांच्या वारसांना तुटपुंजी रक्कम मिळाल्याने त्यांचे आर्थिक उद्वेग सुरू झाले. राज्य सरकारने ही योजना रद्द करावी, अशी मागणी कुहामुंबई राज्य सरकारने कर्मचाऱ्यांच्या संघटनेचे सचिद्विभागीत अविनाश दीड यांनी केली.



शुक्रवारी दिव्या आंदोलन केले. हे आंदोलन १०० टक्के यशस्वी झाल्याचा दावा राज्य सरकारने कर्मचाऱ्यांमार्फत संघटनेचे सचिद्विभागीत विनयास काढकर यांनी केला. राष्ट्रिय पेन्शन योजना हटाव दिव्य पाठून राज्यातील कर्मचाऱ्यांनी दिव्या आंदोलनात उध्दरून सहभागी भेतावा व आंदोलन यशस्वी केले. राजपंडित अधिकारी महाराष्ट्राच्या पाठिंब्यामुळे राज्यातील अधिकाऱ्यांनी व आंदोलनात दिक्कतकाणी सहभागी भेतावा. यापुढे राज्य सरकारने या प्रश्नाकडे दुर्लक्ष केल्यास हिंसेमय संघर्ष संपादव जाण्याचा इशारा काढकर यांनी दिला.

परिवहनमंत्र्यांवर मनसेची टीका

मुंबई | एस्टी कर्मचाऱ्यांच्या आत्महत्येबाबत महाराष्ट्र नवनिर्माण सेनेने राज्यचे परिवहनमंत्री अनिल परब यांना टिका केली आहे. पक्षाचे अधिकारि चित्री यांनी टिपट्या मध्यमामुत या आत्महत्येबाबत अनिल परब, असा सवाल परब यांना विचारला आहे. राज्यात गेल्या काही दिवसांपासून एस्टी कर्मचाऱ्यांच्या आत्महत्येबाबत, घडामोडी बरेच होताना दिसत आहे. याबाबत परिवहनमंत्री परब यांच्यावर टीकाही प्रेक्ष उडविण्यात येत असतानाच

हेमंत टकले यांचे लेखन बहुआयामी

मुंबई | एस्टी कर्मचाऱ्यांच्या आत्महत्येबाबत महाराष्ट्र नवनिर्माण सेनेने राज्यचे परिवहनमंत्री अनिल परब यांना टिका केली आहे. पक्षाचे अधिकारि चित्री यांनी टिपट्या मध्यमामुत या आत्महत्येबाबत अनिल परब, असा सवाल परब यांना विचारला आहे. राज्यात गेल्या काही दिवसांपासून एस्टी कर्मचाऱ्यांच्या आत्महत्येबाबत, घडामोडी बरेच होताना दिसत आहे. याबाबत परिवहनमंत्री परब यांच्यावर टीकाही प्रेक्ष उडविण्यात येत असतानाच

FAIRCHEM ORGANICS LIMITED

Regd. Office: Plot No. A-71, TTC, Thane-Belapur Road, Near Kopar Khairane, NAVI MUMBAI-400 709
Works & Office : 253/P & 312, Village Chekhala, Sanand - Kadi Highway, Taluka Sanand, Dist. Ahmedabad - 382 115, Gujarat. Ph.: (02717) 687 900, (02717) 687 901
Email Id: cs@fairchem.in, Website: www.fairchem.in
CIN: U24200MH2019PLC323176

Sr. No.		Particulars	Quarter ended			Six Months ended		Year ended
			30-Sep-2021	30-Jun-2021	30-Sep-2020	30-Sep-2021	30-Sep-2020	
			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	16,802.62	13,953.33	9,499.98	30,736.10	13,009.33	39,685.16	
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	2,801.86	2,993.30	1,221.75	5,795.16	1,354.27	5,556.08	
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	2,801.86	2,993.30	1,221.75	5,795.16	1,354.27	5,556.08	
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	2,089.74	2,231.20	905.75	4,320.94	1,025.18	4,248.47	
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	2,088.40	2,216.05	911.30	4,304.45	1,020.73	4,201.38	
6	Equity Share Capital (Face value of Rs. 10/- each)	1,302.09	1,302.09	1,302.09	1,302.09	1,302.09	1,302.09	
7	Other Equity (as per balance sheet of the previous accounting year)							15,571.36
8	Earnings Per Share (Face value of Rs. 10/- each) - In Rupees	16.05	17.14	6.96	33.18	7.87	32.63	
	diluted	16.05	17.14	6.96	33.18	7.87	32.63	

Notes:
 1 The above is an extract of the detailed format of Unaudited Financial Results for the quarter and six months ended September 30, 2021 filed with the Stock Exchanges under Regulation 33 of SEBI (LODR) Regulations, 2015. The full format of the Financial Results are available on the websites of the Stock Exchanges (www.bseindia.com, www.nseindia.com) and the Company (www.fairchem.in)

**For and on behalf of the Board of Directors,
 For Fairchem Organics Limited,**

Sd/-
Nahoosh Jariwala
 Managing Director
 DIN 00012412

Place : Chekhala, Taluka Sanand, Dist. AHMEDABAD
Date : October 28, 2021

मुद्दे आपके राय आपकी

**अब खबरें सिर्फ देखें नहीं
उनका हिस्सा भी बनें,
क्योंकि जब मुद्दे हों आपके तो आपकी
राय ज़रूरी है.**

OPINION INDIA का

मीनाक्षी कंडवाल

हर रात 10 बजे

हमारे नए हिंदी न्यूज़ चैनल पर

**अब बदलोगा भारत
नवभारत बनोगा नवभारत**

Available on: AIRTEL DIGITAL TV - 327, TATA SKY - 528, HATHWAY - 321, SITI - 1165
 FASTWAY TRANSMISSION - 721, GTPL HATHWAY - 134, INDIGITAL - 313/316/322.

ajanta pharma limited

**Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67,
 Phone - +91-22-66061000, Fax - +91-22-66061200
 CIN - L24230MH1979PLC022059
 Email - info@ajantapharma.com, Website - www.ajantapharma.com**

Extract of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2021

Particulars	₹ In Crore			
	Quarter ended 30-Sep-21	Half year ended 30-Sep-21	Quarter ended 30-Sep-20	Year ended 31-Mar-21
1 Total Income from Operations	894.80	1,632.79	715.91	2,889.69
2 Net Profit for the period before tax (before exceptional and/or extraordinary items)	260.42	480.87	249.24	900.18
3 Net Profit for the period before tax (after exceptional and/or extraordinary items)	260.42	480.87	249.24	900.18
4 Net Profit for the period after tax (after exceptional and/or extraordinary items)	195.94	369.69	170.22	653.87
5 Total Comprehensive Income for the period (comprising profit for the period after tax and other comprehensive income after tax)	191.69	363.11	165.80	647.42
6 Equity Share Capital	17.39	17.39	17.54	17.39
7 Reserve (excluding Revaluation Reserve) as shown in audited balance sheet				2,978.24
8 Earnings Per Share (FV of ₹ 2/- each)				
(a) Basic - in ₹	22.64	42.72	19.51	75.09
(b) Diluted - in ₹	22.64	42.72	19.51	75.09

Key information on Standalone Financial Results :

Particulars	Quarter ended 30-Sep-21	Half year ended 30-Sep-21	Quarter ended 30-Sep-20	Year ended 31-Mar-21
Total Income from Operations	823.71	1,566.43	676.51	2,718.59
Profit Before Tax	254.79	487.88	308.53	902.09
Profit After Tax	196.85	390.31	225.22	675.64
Total Comprehensive Income	196.54	389.67	224.66	674.31

Notes:

- The above unaudited financial results have been reviewed by Audit Committee and thereafter approved by the Board of Directors at their meeting held on 29 October 2021.
- Board of Directors have approved payment of interim dividend on 29 October 2021 of ₹ 9.50 per equity share of face value of ₹ 2 each.
- The above is an extract of the detailed format of Quarterly Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the standalone and consolidated financial results for the quarter and half year ended 30 September 2021 are available on stock exchange websites www.nseindia.com and www.bseindia.com and on Company's website www.ajantapharma.com.

**By order of the Board
 For Ajanta Pharma Ltd.**

Mumbai, 29 October 2021

Yogesh M. Agrawal
 Managing Director